Earnings ·
Filana Therapeutics reports Q3 net loss of $10.7M; FDA lifts clinical hold on simufilam
FLNAFilana Therapeutics, Inc.
Filana Therapeutics reported a third-quarter net loss of $10.7 million, or $0.22 per share, with cash and cash equivalents standing at $47.0 million as of September 30, 2026. The company announced that the FDA lifted its clinical hold on the investigational new drug application for simufilam in TSC-related epilepsy in September, allowing preparations to advance toward a Phase 2a study expected to begin patient screening by Q1 2027. R&D expenses decreased slightly to $3.9 million from $4.0 million in the prior year period. The company also noted that $31.25 million was transferred into escrow for potential securities litigation settlement. Filana Therapeutics is a biotechnology company focused on developing novel therapies for central nervous system disorders.